U.S. overdose deaths fell for the third straight year in 2025. CDC provisional data released May 2026 projects 69,973 deaths for the full year—down 14% from 2024 and about 38% below the 2022 peak of 112,000.
In April 2026, the Trump administration banned federal funding for fentanyl test strips, overturning prior policy. Medetomidine, a veterinary sedative 300 times more potent than xylazine and not reversible by naloxone, is now spreading through drug supplies in Chicago, Philadelphia, and Pittsburgh. Several western states—Arizona, New Mexico, Colorado—are seeing deaths climb again.
Why it matters
Drug overdoses kill more Americans under 45 than any other cause—and new federal cuts are testing whether three years of progress hold.
Questions about this story
Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.
No questions yet — be the first to ask.
Key Indicators
69,973
Predicted annual overdose deaths
CDC provisional estimate for full year 2025, released May 2026
14%
Year-over-year decline
Continued decrease in 2025, though slower than the 27% drop in 2024
112,109
2022 peak deaths
Highest annual overdose toll in U.S. history
$56B
Settlement funds allocated
Total awarded to states and localities from opioid lawsuits
4+
Western states with rising deaths
Arizona (+21%), New Mexico (+22%), Colorado (+11%), and North Dakota (+8%) all saw increases in latest data
17 events
Latest: May 13th, 2026 · 4 months ago
Showing 8 of 17
JK to step
Tap a bar to jump to that date
Jump to
May 2026
CDC Projects ~70,000 Deaths for Full Year 2025—Third Straight Decline
LatestData Release
Provisional data released by CDC's National Vital Statistics System shows approximately 69,973 overdose deaths for all of 2025, down 14% from 2024. The decline continues but has slowed sharply from the 27% drop recorded the year before.
April 2026
SAMHSA Bans Federal Funding for Fentanyl Test Strips
Policy
SAMHSA guidance prohibits federal grant funds from purchasing fentanyl test strips and other drug-checking supplies—reversing prior policy. Organizations distributing hundreds of thousands of strips quarterly now face funding gaps.
CDC Warns of Medetomidine Spreading Through Illicit Drug Supply
Emerging Threat
CDC issued a health alert warning that medetomidine—a veterinary sedative up to 300 times more potent than xylazine—is replacing xylazine in parts of Chicago, Philadelphia, and Pittsburgh. Naloxone does not reverse its effects, and abrupt withdrawal can be life-threatening.
January 2026
Trump Administration Reverses $2 Billion SAMHSA Grant Cuts After 24-Hour Backlash
Policy
One day after abruptly terminating roughly $2 billion in addiction and mental health grants to about 2,000 organizations, the Trump administration reversed the cuts following immediate legal and political pressure.
CDC Reports 21% Decline Through August 2025
Data Release
New provisional data predicts 72,836 overdose deaths for 12 months ending August 2025. Decline continues for second consecutive year, though rate of decrease has slowed. Deaths down in 45 states.
January 2025
$7.4 Billion Purdue/Sackler Settlement Finalized
Legal
New York AG announces landmark settlement with Purdue Pharma and Sackler family. Sacklers pay up to $6.5 billion over 15 years; Purdue contributes $900 million. Largest individual opioid settlement.
May 2024
CDC Reports 27% Annual Decline—Largest Ever
Data Release
Provisional data shows approximately 80,000 deaths in 12 months ending early 2024, down from 110,000 the previous year. Largest single-year reduction in overdose deaths ever recorded.
November 2023
Biden-Xi Summit Revives Fentanyl Cooperation
Diplomatic
U.S. and China agree to resume counternarcotics cooperation frozen since 2019. China shuts down some precursor suppliers and resumes sharing suspicious shipment data with international authorities.
August 2023
Overdose Deaths Begin Sustained Decline
Turning Point
CDC data identifies August 2023 as inflection point when national overdose death rates reversed course. Deaths decline for 15 consecutive months—the longest sustained drop in decades.
July 2023
White House Declares Xylazine Emerging Threat
Policy
ONDCP designates fentanyl mixed with xylazine ('tranq') as emerging drug threat. The veterinary sedative, found in 30% of seized fentanyl, doesn't respond to naloxone and causes severe wounds.
March 2023
FDA Approves Over-the-Counter Naloxone
Policy
Narcan nasal spray approved for sale without prescription in pharmacies, convenience stores, and online. First OTC naloxone product in U.S. history, removing barrier to overdose reversal medication.
January 2023
X-Waiver Eliminated for Buprenorphine
Policy
Consolidated Appropriations Act removes requirement for special waiver to prescribe addiction treatment medication. Any provider with DEA Schedule III authority can now prescribe buprenorphine, expanding treatment access.
December 2022
Overdose Deaths Peak at 112,000
Milestone
Annual overdose deaths hit all-time high of 112,109 Americans—more than car accidents, gun violence, or any single disease for those under 45. Fentanyl involved in roughly 70% of deaths.
May 2019
China Imposes Class-Wide Fentanyl Controls
Policy
Under U.S. pressure, China schedules all fentanyl-related substances as controlled. Direct fentanyl shipments to U.S. largely cease, but precursor chemical trade to Mexican cartels continues.
January 2013
Wave Three: Synthetic Opioids Transform Crisis
Escalation
Illicitly manufactured fentanyl enters drug supply. Fifty times more potent than heroin, it causes deaths to accelerate dramatically. By 2017, synthetic opioids become leading driver of overdose deaths.
January 2010
Wave Two: Heroin Deaths Spike
Escalation
As prescription opioid restrictions tighten, users shift to cheaper heroin flooding in from Mexico. Heroin overdose rate increases fivefold between 2010 and 2016.
January 1999
Wave One Begins: Prescription Opioid Deaths Rise
Origin
CDC identifies start of opioid overdose epidemic, driven by aggressive marketing of OxyContin and other prescription painkillers. Deaths from prescription opioids begin steady climb that will continue for over two decades.
Discussed by: Drug Policy Alliance, Brookings Institution researchers, some public health officials
If current interventions maintain momentum—naloxone saturation, treatment access expansion, settlement funding deployment—deaths could fall below 60,000 by 2027, approaching pre-fentanyl levels. This requires sustained political commitment to harm reduction regardless of administration, continued China cooperation on precursors, and billions in settlement funds reaching frontline services rather than general budgets.
2
Decline Stalls as New Synthetic Threats Emerge
Likely
Discussed by: DEA analysts, Filter Magazine, harm reduction advocates
The slowing rate of decline in 2025 data may signal approaching plateau. Xylazine contamination continues rising—present in 75% of samples at some testing sites. Nitazenes, even more potent synthetic opioids, have appeared in isolated cases. If new adulterants spread or harm reduction funding contracts, progress could reverse. Regional disparities remain stark.
3
Policy Reversal Triggers Renewed Increase
Possible
Discussed by: Georgetown O'Neill Institute, harm reduction organizations, some public health researchers
The Trump administration's mixed signals on harm reduction—endorsing naloxone and test strips while emphasizing enforcement and opposing supervised consumption—could reduce funding for syringe services and community-based programs. If federal support contracts while settlement funds are diverted to non-evidence-based uses, deaths could climb again, particularly in underserved communities.
4
Racial Disparities Widen Even as Total Deaths Fall
Likely
Discussed by: JAMA Network Open researchers, Health Affairs analysts, Baltimore health officials
Recent data shows overdose deaths falling faster among white Americans than Black, Hispanic, and Indigenous populations. If naloxone access and treatment expansion don't reach communities of color equitably, aggregate statistics could mask worsening crisis for specific populations. Baltimore 2024 data already shows concentration of deaths among older Black men increasing even as overall numbers decline.
5
Fentanyl Test Strip Ban Reversed by Congress or HHS
Uncertain
Resolves by End of 2026
Discussed by: Senator Jacky Rosen and bipartisan Senate colleagues, Drug Policy Alliance (May 2026)
Senators from both parties formally demanded in May 2026 that the administration reverse the SAMHSA guidance banning federal funding for fentanyl test strips. If Congress acts via appropriations language or HHS rescinds the guidance, harm reduction programs that distributed hundreds of thousands of strips quarterly could resume federal funding.
Discussed by: CDC Health Alert Network (April 2026), American Academy of Family Physicians (March 2026)
Medetomidine has already displaced xylazine in parts of Chicago, Philadelphia, and Pittsburgh. If it spreads to other major cities, first responders will face overdoses that naloxone alone cannot manage, and emergency withdrawal protocols not yet widely established will be needed.
Historical Context
3 moments from history that rhyme with this story — and how they unfolded.
1 of 3
1984-1997
Crack Cocaine Epidemic Response (1980s-1990s)
Crack cocaine spread rapidly through American cities, causing hospital emergencies to surge from 23,500 to 94,000 between 1984 and 1987. Congress responded with the Anti-Drug Abuse Act of 1986, creating 100:1 sentencing disparity between crack and powder cocaine.
Then
Federal prison population for drug offenses exploded from 50,000 in 1980 to 400,000 by 1997. Black communities, comprising 80% of crack users, bore disproportionate impact.
Now
Mass incarceration devastated communities without reducing drug use. The punitive approach is now widely viewed as a failure, influencing current emphasis on treatment over imprisonment.
Why this matters now
The crack response shows consequences of treating addiction as primarily a criminal matter. The relative decline in opioid deaths coincides with policy shift toward public health approaches—though enforcement remains substantial, treatment and harm reduction now receive significant resources.
2 of 3
1984-1996
AIDS Crisis Harm Reduction (1980s-1990s)
As HIV spread among injection drug users, activists pioneered needle exchange programs over fierce political opposition. First U.S. syringe exchange opened in Tacoma in 1988. Federal funding for such programs was banned from 1988 to 2016.
Then
Cities with syringe exchanges saw HIV transmission among drug users drop by 50-80%. Programs also connected users to treatment and healthcare.
Now
Research established harm reduction as evidence-based public health. Federal funding ban lifted in 2016. By 2024, syringe services operate in most states and serve as distribution points for naloxone and fentanyl test strips.
Why this matters now
Current overdose decline builds on harm reduction infrastructure developed during AIDS crisis. Naloxone distribution often occurs through syringe services. The path from controversial intervention to mainstream policy took decades—fentanyl test strip legalization followed similar trajectory in compressed timeframe.
3 of 3
2001-present
Portugal Drug Decriminalization (2001)
Facing Europe's worst heroin crisis—1% of the population addicted—Portugal decriminalized personal drug possession and redirected 90% of drug enforcement spending to health services. Police refer users to 'dissuasion commissions' offering voluntary treatment rather than arrest.
Then
HIV infections from injection drug use dropped 90%. Overdose deaths fell from 80 per million to 6 per million by 2021—a 93% reduction.
Now
Portugal now has Europe's lowest overdose rate, one-fiftieth of the U.S. rate. The model influenced drug policy debates worldwide, though recent disinvestment has caused some backsliding.
Why this matters now
Portugal demonstrates that health-centered drug policy can produce sustained mortality reductions. The U.S. decline incorporates some elements—expanded treatment, harm reduction—but without decriminalization and with far less funding relative to need.
